De-risking prostate cancer screening with ClarityDX Prostate
ClarityDX Prostate builds upon the utility of clinical features and blood-based biomarkers to determine a patient’s risk of having aggressive prostate cancer. This empowers patients and their healthcare providers make more informed healthcare decisions.
Dr. John Lewis
CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta
Recent News
Research supporting ClarityDX Prostate published in Nature Digital Medicine
Published 26 June 2024 Development of an effective predictive [...]
Nanostics Prostate Cancer Screening Test, ClarityDX Prostate®, becomes accessible to men in British Columbia, Saskatchewan, and Ontario
EDMONTON, AB, June 5, 2024 /CNW/ - Nanostics Inc., a precision health [...]
Nanostics partners with CDL Laboratories to Provide Access to ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer
Quebec-based CDL Laboratories will now offer the validated ClarityDX [...]
2024 PROSTATE CANCER SCREENING UPDATE
Our success is possible thanks to the support of our many Canadian and international collaborators, funders, and partners.
